August 28, 2025

First Generic GLP-1 for Weight Loss Approved

FDA approves Teva’s generic Saxenda (liraglutide) with adult and adolescent indications and a boxed thyroid tumor warning.

Conexiant

August 19, 2025

Bedtime Cyclobenzaprine Relieves Fibromyalgia: Randomized Trial

Researchers found bedtime sublingual cyclobenzaprine reduced pain versus placebo and improved sleep, fatigue, and function with mostly mild oral adverse events.

Conexiant

August 15, 2025

FDA Approves Non-Opioid Fibromyalgia Therapy

Tonmya reduces fibromyalgia pain versus placebo in phase 3 trials, offering a non-opioid option with a generally well-tolerated safety profile.

Conexiant

August 12, 2025

Advanced-Practice Providers Filling Rural ER Gaps

Rural emergency rooms across the U.S. are increasingly staffed by physician assistants and nurse practitioners instead of physicians, raising debates over care quality, staffing shortages, and access to emergency services.

KFF Health News

August 11, 2025

FDA Approves Ketamine Product for Surgical Pain Management

PharmaTher has received FDA approval for KETARx, a ketamine therapy for surgical pain management.

Conexiant

August 06, 2025

New Preventive Option Approved for Pediatric Migraine

The FDA has approved Ajovy (fremanezumab-vfrm) for preventive treatment of episodic migraine in pediatric patients aged 6 to 17 years weighing 45 kg or more, expanding its use beyond adults.

Conexiant

August 04, 2025

Nitazenes: A Hidden Threat Stronger Than Fentanyl

The drug can be hundreds of times stronger than heroin and up to five times more potent than fentanyl.

Conexiant

July 31, 2025

‘Victim-Blaming’ in Public Health?

As Trump’s health officials push personal responsibility, critics warn their rhetoric blames patients, shapes policy, and risks deepening health inequalities.

KFF Health News

May 28, 2024

Former Doc Accused of Murder-for-Hire, Sentenced for Distribution

Former doctor sentenced to 90 months in federal prison for illegal opioid distribution and health care fraud.

Conexiant